BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23061804)

  • 1. Ruxolitinib: in the treatment of myelofibrosis.
    Yang LP; Keating GM
    Drugs; 2012 Nov; 72(16):2117-27. PubMed ID: 23061804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
    N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM
    Haematologica; 2013 Dec; 98(12):1865-71. PubMed ID: 24038026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
    Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV; Winton EF; Natrajan K; Odenike O; Claxton D; Peng W; O'Neill P; Erickson-Viitanen S; Leopold L; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Hematol Oncol; 2013 Oct; 6(1):81. PubMed ID: 24283202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
    Talpaz M; Erickson-Viitanen S; Hou K; Hamburg S; Baer MR
    J Hematol Oncol; 2018 Aug; 11(1):101. PubMed ID: 30086777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
    Mascarenhas J; Kremyanskaya M; Patriarca A; Palandri F; Devos T; Passamonti F; Rampal RK; Mead AJ; Hobbs G; Scandura JM; Talpaz M; Granacher N; Somervaille TCP; Hoffman R; Wondergem MJ; Salama ME; Colak G; Cui J; Kiladjian JJ; Vannucchi AM; Verstovsek S; Curto-García N; Harrison C; Gupta V
    J Clin Oncol; 2023 Nov; 41(32):4993-5004. PubMed ID: 36881782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.
    Mesa RA; Cortes J
    J Hematol Oncol; 2013 Oct; 6():79. PubMed ID: 24283870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
    Yacoub A; Borate U; Rampal RK; Ali H; Wang ES; Gerds AT; Hobbs G; Kremyanskaya M; Winton E; O'Connell C; Goel S; Oh ST; Schiller G; McCloskey J; Palmer J; Holmes H; Hager S; Assad A; Erickson-Viitanen S; Zhou F; Daver N
    Blood Adv; 2024 Mar; 8(6):1515-1528. PubMed ID: 38290135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to.
    Li Y; Zhu S; Liu W; Ming J; Wang X; Hu X
    Ann Hematol; 2020 Jun; 99(6):1161-1176. PubMed ID: 32333155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
    Verstovsek S; Foltz L; Gupta V; Hasserjian R; Manshouri T; Mascarenhas J; Mesa R; Pozdnyakova O; Ritchie E; Veletic I; Gamel K; Hamidi H; Han L; Higgins B; Trunzer K; Uguen M; Wang D; El-Galaly TC; Todorov B; Gotlib J
    Haematologica; 2023 Oct; 108(10):2730-2742. PubMed ID: 37165840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
    Oh ST; Verstovsek S; Gupta V; Platzbecker U; Devos T; Kiladjian JJ; McLornan DP; Perkins A; Fox ML; McMullin MF; Mead AJ; Egyed M; Mayer J; Sacha T; Kawashima J; Huang M; Strouse B; Mesa R
    EJHaem; 2024 Feb; 5(1):105-116. PubMed ID: 38406514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor.
    Tremblay D; Dougherty M; Mascarenhas J; Gallagher EJ
    Front Endocrinol (Lausanne); 2023; 14():1141029. PubMed ID: 37455900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
    Gupta V; Oh S; Devos T; Dubruille V; Catalano J; Somervaille TCP; Platzbecker U; Giraldo P; Kosugi H; Sacha T; Mayer J; Illes A; Ellis C; Wang Z; Gonzalez Carreras FJ; Strouse B; Mesa R
    Leuk Lymphoma; 2024 Mar; ():1-13. PubMed ID: 38501751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
    Harrison C; Vannucchi AM
    Ther Adv Hematol; 2012 Dec; 3(6):341-54. PubMed ID: 23606937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial.
    Verstovsek S; Talpaz M; Wadleigh M; Isidori A; Te Boekhorst P; Savona MR; Bose P; Pozdnyakova O; Mesa R; El-Galaly TC; O'Sullivan J; Gamel K; Higgins B; Katakam S; Todorov B; Trunzer K; Harrison CN
    Haematologica; 2024 Jun; 109(6):1977-1983. PubMed ID: 38268448
    [No Abstract]   [Full Text] [Related]  

  • 16. A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort.
    Tavares R; Souza CA; Paley C; Bouard C; Tiwari R; Pasquini R
    Hematol Transfus Cell Ther; 2020; 42(1):46-53. PubMed ID: 31235325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
    Kang C
    Drugs; 2024 Apr; ():. PubMed ID: 38625661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.
    Chiu CY; John TM; Matsuo T; Wurster S; Hicklen RS; Khattak RR; Ariza-Heredia EJ; Bose P; Kontoyiannis DP
    J Fungi (Basel); 2024 Mar; 10(4):. PubMed ID: 38667935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
    Gupta V; Yacoub A; Mesa RA; Harrison CN; Vannucchi AM; Kiladjian JJ; Deeg HJ; Fazal S; Foltz L; Mattison RJ; Miller CB; Parameswaran V; Brown P; Hernandez C; Wang J; Talpaz M
    Leuk Lymphoma; 2024 Jun; ():1-11. PubMed ID: 38838026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib-A Real-Life Longitudinal Study.
    Stoeva V; Mihaylov G; Mitov K; Petrova G; Tachkov K
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.